Bioprocessing
Totient advances anti-SARS-CoV-2 antibodies with funding, partnerships
Ginkgo Bioworks and artificial intelligence drug discovery firm Totient have partnered to identify antibodies effective against the novel coronavirus and develop associated therapeutics.
New AI-based company targets discovery of new protein-based therapeutics
Flagship Pioneering has launched Generate Biomedicines, a new company that will use its machine learning-powered platform for the rapid discovery of new drugs across a range of modalities, including antibodies, peptides, enzymes, and cytokines, and entirely new protein-based therapeutics.
Ligand expands antibody discovery capabilities with acquisitions
Ligand Pharmaceuticals has acquired xCella Biosciences and Taurus Biosciences to strengthen its OmniAb technology platform for antibody discovery.
Making CRISPR safer with new enzyme-based prediction tool
A new technique will help scientists choose the best available gene editing option for any given indication, making CRISPR technology safer, cheaper, and more effective. The tool is outlined in a September 7 article in Nature Biotechnology.  Discuss
Canbridge, UMass partner on gene therapies for neuromuscular diseases
Canbridge Pharmaceuticals has expanded its gene-therapy partnership with the University of Massachusetts (UMass) Medical School.
Thermo Fisher opens new bioprocessing collaboration center
Thermo Fisher Scientific has opened a new bioprocessing collaboration center in St. Louis to accelerate innovations in biologics manufacturing.
MilliporeSigma expands antibody-drug conjugate manufacturing
MilliporeSigma is expanding its high-potent active pharmaceutical ingredient and antibody-drug conjugate manufacturing capabilities with a $65 million investment at its Madison, WI, facility.
Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of customization, manufacturing expertise, and years' worth of knowledge.  Discuss
Exelixis enters collaborations for antibody drug conjugates
Exelixis has entered into two separate partnerships with Catalent and NBE Therapeutics for the discovery and development of multiple antibody-drug conjugates for oncology applications to build out the pipeline for Cabometyx, its flagship product.
New CRISPR-repressor system improves efficiency of gene therapies
Researchers have developed a CRISPR-based system that can simultaneously provide transcriptional control and gene editing on demand to improve the efficacy of gene therapies. The details were published in Nature Cell Biology on September 3.  Discuss
Conferences
ESMO Virtual Congress 2020
September 14-29
Online
BioProcess International West
September 21-25
Online
BioProcess International
September 21-25
Online
ASGCT 2020 Policy Summit
September 23-25
Online
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter